Hestia Insight Inc. (HSTA) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören Hestia Insight Inc. (HSTA), 0 değerindeki bir Technology şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 39/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026Hestia Insight Inc. (HSTA) Teknoloji Profili ve Rekabetçi Konumu
Hestia Insight Inc. provides strategic consulting and capital market advisory services, primarily targeting micro, small, and medium-sized companies in the healthcare, biotech, and fintech sectors. Additionally, they offer healthcare management, technology development, and sales support, positioning them as a multifaceted service provider in specialized markets.
Yatırım Tezi
Hestia Insight Inc. presents a unique investment proposition as a consulting and advisory firm operating at the intersection of healthcare, biotech, and fintech. The company's focus on micro, small, and medium-sized businesses allows it to cater to a niche market often underserved by larger consulting firms. Key value drivers include the potential for revenue growth through expansion of its service offerings and client base within its target sectors. However, investors may want to evaluate the risks associated with the company's small size, limited resources, and dependence on key personnel. The company's P/E ratio is -0.78 and Beta is -0.31 as of March 16, 2026.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Hestia Insight Inc. operates with a small team of 3 employees, indicating a lean operational structure.
- The company's focus on micro, small, and medium-sized businesses in healthcare, biotech, and fintech allows for specialized service offerings.
- Hestia Insight provides a diverse range of services, including strategic consulting, capital market advisory, healthcare management, and technology development.
- The company's negative P/E ratio of -0.78 suggests that it is currently not profitable.
- The company's beta of -0.31 indicates a low correlation with the overall market, potentially offering some downside protection.
Rakipler & Benzerleri
Güçlü Yönler
- Specialized focus on healthcare, biotech, and fintech sectors.
- Integrated service offerings covering consulting, advisory, and technology development.
- Agile and responsive due to small company size.
- Established presence in Las Vegas.
Zayıflıklar
- Limited financial resources and capital.
- High dependence on key personnel.
- Small team size may limit scalability.
- OTC market listing may reduce investor confidence.
Katalizörler
- Upcoming: Potential partnerships with fintech companies to expand service offerings in the fintech sector.
- Ongoing: Increasing demand for healthcare technology solutions for neurological and psychiatric disorders.
- Ongoing: Expansion of healthcare management services to address the needs of micro and small healthcare providers.
Riskler
- Potential: Limited financial resources may constrain growth initiatives and expansion plans.
- Potential: Dependence on key personnel could disrupt operations if they leave the company.
- Ongoing: Intense competition from larger consulting firms with greater resources and brand recognition.
- Potential: Evolving regulatory landscape in healthcare and fintech may require costly compliance efforts.
- Ongoing: OTC market listing may reduce investor confidence and limit access to capital.
Büyüme Fırsatları
- Expansion of Healthcare Technology Development: Hestia Insight can capitalize on the growing demand for innovative healthcare technologies by expanding its development capabilities. The global healthcare technology market is projected to reach $280 billion by 2028, presenting a significant opportunity for Hestia Insight to develop and commercialize new solutions for neurological and psychiatric disorders. Timeline: 2-3 years.
- Strategic Partnerships with Fintech Companies: Collaborating with emerging fintech companies to provide specialized consulting services can drive growth. The fintech market is experiencing rapid growth, with a projected market size of $509 billion by 2029. Hestia Insight can leverage its expertise in capital markets and healthcare to offer valuable insights to fintech companies seeking to disrupt the healthcare industry. Timeline: 1-2 years.
- Increased Focus on Healthcare Management Services: The demand for efficient healthcare management services is increasing as healthcare providers seek to optimize operations and improve patient outcomes. Hestia Insight can expand its healthcare management offerings to address this need, targeting micro and small healthcare providers that may lack the resources to implement sophisticated management systems. Timeline: Ongoing.
- Geographic Expansion Beyond Las Vegas: Hestia Insight can explore opportunities to expand its geographic reach beyond Las Vegas, targeting other regions with a high concentration of healthcare, biotech, and fintech companies. This expansion can be achieved through strategic partnerships, remote service delivery, and the establishment of satellite offices. Timeline: 3-5 years.
- Development of Proprietary Healthcare Analytics Platform: Creating a proprietary healthcare analytics platform can provide Hestia Insight with a competitive advantage and generate recurring revenue streams. This platform can leverage data analytics and machine learning to provide insights into patient behavior, treatment outcomes, and market trends, enabling healthcare providers to make more informed decisions. Timeline: 2-3 years.
Fırsatlar
- Expansion into new geographic markets.
- Development of proprietary healthcare technology solutions.
- Strategic partnerships with complementary businesses.
- Increased demand for specialized consulting services in target sectors.
Tehditler
- Intense competition from larger consulting firms.
- Evolving regulatory landscape in healthcare and fintech.
- Economic downturn impacting client spending.
- Technological disruptions rendering existing services obsolete.
Rekabet Avantajları
- Specialized expertise in the intersection of healthcare, biotech, and fintech.
- Focus on micro, small, and medium-sized businesses, a niche often underserved by larger firms.
- Integrated service offerings spanning consulting, advisory, technology development, and sales support.
HSTA Hakkında
Hestia Insight Inc., formerly known as Luxshmi Investments, Inc. until its name change in May 2019, is a Las Vegas-based firm providing strategic consulting and capital market advisory services. The company focuses on serving micro, small, and medium-sized enterprises within the healthcare, biotech, and fintech sectors. Hestia Insight offers a range of services, including healthcare management and patient services, development of healthcare technologies and analysis for neurological and psychiatric disorders, and medical supply sales support and management. The company also provides sales and marketing guidance to its clients. Hestia Insight's multifaceted approach aims to support its clients through various stages of growth and development, leveraging its expertise in both the financial and healthcare technology domains. The company operates with a small team of three employees.
Ne Yaparlar
- Provides strategic consulting services to micro, small, and medium-sized companies.
- Offers capital market advisory services.
- Delivers healthcare management and patient services.
- Develops healthcare technologies and analysis for neurological and psychiatric disorders.
- Provides medical supply sales support and management.
- Offers sales and marketing guidance and services.
İş Modeli
- Generates revenue through consulting fees for strategic advisory services.
- Earns fees from capital market advisory services, such as assisting with fundraising and M&A transactions.
- Derives income from healthcare management and patient service contracts.
- Potentially generates revenue from the licensing or sale of developed healthcare technologies.
Sektör Bağlamı
Hestia Insight Inc. operates within the competitive landscape of consulting and advisory services, specifically targeting the healthcare, biotech, and fintech sectors. These sectors are characterized by rapid innovation, evolving regulatory environments, and significant capital flows. The market for consulting services in these sectors is driven by the need for specialized expertise in areas such as regulatory compliance, technology adoption, and market access. Hestia Insight's focus on micro, small, and medium-sized businesses positions it to capitalize on the demand for tailored solutions in these dynamic industries.
Kilit Müşteriler
- Micro-sized companies in the healthcare sector.
- Small-sized businesses in the biotech industry.
- Medium-sized enterprises in the fintech sector.
Finansallar
Grafik & Bilgi
Hestia Insight Inc. (HSTA) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Hovde Group Upgrades SouthState Bank (SSB) to Outperform
Yahoo Finance · 25 Mar 2026
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
HSTA için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
HSTA için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, HSTA'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Edward C. Lee
Managing Director
Edward C. Lee serves as the Managing Director of Hestia Insight Inc., overseeing a small team of three employees. Information regarding his detailed career history, education, and previous roles is not available. His leadership is pivotal in guiding the strategic direction and operational activities of the company, particularly in the areas of consulting and capital market advisory services.
Sicil: Due to limited information available, Edward C. Lee's specific achievements and strategic decisions at Hestia Insight Inc. cannot be comprehensively assessed. However, under his leadership since May 2019, the company has focused on providing services to micro, small, and medium-sized companies in the healthcare, biotech, and fintech sectors.
HSTA OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hestia Insight Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, which increases investment risk. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, potentially leading to less transparency and greater volatility.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure increases information asymmetry and investment risk.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the potential for fraud and manipulation.
- OTC Other companies may have a higher risk of delisting or going out of business.
- Limited analyst coverage and institutional interest can result in less price discovery and valuation uncertainty.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures, if any.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and ownership.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Company's incorporation date and history.
- Physical business address and contact information.
- Presence of a functional website and online presence.
- Industry affiliations and memberships.
- Positive client testimonials or case studies (if available).
HSTA Hakkında Sıkça Sorulan Sorular
HSTA için değerlendirilmesi gereken temel faktörler nelerdir?
Hestia Insight Inc. (HSTA) şu anda yapay zeka skoru 39/100, düşük puanı gösteriyor. Temel güçlü yan: Specialized focus on healthcare, biotech, and fintech sectors.. İzlenmesi gereken birincil risk: Potential: Limited financial resources may constrain growth initiatives and expansion plans.. Bu bir finansal tavsiye değildir.
HSTA MoonshotScore'u nedir?
HSTA şu anda MoonshotScore'da 39/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
HSTA verileri ne sıklıkla güncellenir?
HSTA fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler HSTA hakkında ne diyor?
HSTA için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
HSTA'a yatırım yapmanın riskleri nelerdir?
HSTA için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Limited financial resources may constrain growth initiatives and expansion plans.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
HSTA'ın P/E oranı nedir?
HSTA için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için HSTA'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
HSTA aşırı değerli mi, yoksa düşük değerli mi?
Hestia Insight Inc. (HSTA)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
HSTA'ın temettü verimi nedir?
Hestia Insight Inc. (HSTA) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited information available on Hestia Insight Inc. due to its OTC listing and small market capitalization.
- Financial data is limited and may not be fully reliable.
- AI analysis pending, which may provide additional insights.